Skip to main content

Table 3 Combination indices in drug combination studies of irinotecan and the multi-kinase inhibitors sorafenib and sunitinib

From: Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition

Inhibitor, CI

BT 12

BT 16

KCCF1

Sorafenib

0.7

0.8

0.9

Sunitinib

0.9

0.3

0.4